MedTrace Logo

Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome

NCT00362531 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2006-08-10

No results posted yet for this study

Summary

Idiopathic membranous nephropathy (IMN) is one of the most common forms of nephrotic syndrome (NS) in adults and is usually treated by corticosteroids in combination with cytotoxic drugs especially cyclophosphamide or cyclosporine. Tacrolimus, a new immunosuppressive agent, was proved to be effective in treating refractory NS. Whether it is effective in IMN has not been reported. We therefore undertook a multi-center, controlled study to investigate the efficacy and safety profile of tacrolimus compared with cyclophosphamide in the treatment of patients with idiopathic membranous nephropathy and nephrotic syndrome.

Conditions

  • Idiopathic Membranous Nephropathy
  • Nephrotic Syndrome

Interventions

DRUG

tacrolimus combined with prednisone

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Haiyan WANG, MD · Renal Division, Peking University First Hospital

  • Jianghua Chen, MD · Department of Nephrology, First Hospital of Zhejiang University

  • Xuewang Li, MD · Department of Nephrology, Peking Union Medical College Hospital

  • Fuming Lu, MD · Department of Nephrology, Huashan Hospital, Fudan University

  • Feifei Xu, MD · Department of Nephrology, First Hospital of Wenzhou Medical College

  • Jiaqi Qian, MD · Department of Nephrology, Renji Hospital of Shanghai

  • Fanfan Hou, MD · Department of Nephrology, Nanfang Hospital, First Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2007-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00362531 on ClinicalTrials.gov